Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
September 12 2023 - 7:30PM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines, today announced that it will host an Investor and Analyst
Event on September 13, 2023 at 8:30 a.m. ET. During the webcast and
conference call, members of the Ocugen leadership team and key
opinion leaders will discuss updated results from the Phase 1/2
trial of OCU400 for the treatment of retinitis pigmentosa (RP) and
Leber congenital amaurosis (LCA).
The event will feature:
Shankar Musunuri, PhD, MBA, Chairman, CEO and Co-founder,
Ocugen
Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research,
Development & Medical, Ocugen
Huma Qamar, MD, MPH, Head of Clinical Development and Medical
Affairs, Ocugen
David Birch, PhD, Scientific Director, Retina Foundation of the
Southwest, Principal investigator of the study
Byron L. Lam, MD, Mark J. Daily Professor, Bascom Palmer Eye
Institute, University of Miami, Principal investigator of the
study
Lejla Vajzovic, MD, FASRS, Associate Professor of Ophthalmology
with Tenure, Director of Duke Vitreoretinal Fellowship Program at
Duke Eye Center and Duke University School of Medicine and leader
in gene-therapy research
Webcast and Conference Call Details
Dial-in Numbers: (800) 715-9871 for U.S. callers and (646)
307-1963 for international callersConference ID: 7803227
Webcast: Available on the events section of the
Ocugen investor site
A replay of the call and archived webcast will be available for
approximately 45 days following the event on the
Ocugen investor site.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines that
improve health and offer hope for patients across the globe. We are
making an impact on patient’s lives through courageous
innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on Twitter and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis presentation contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements. Such
statements include, but are not limited to, statements regarding
our clinical development activities and related anticipated
timelines. Such statements are subject to numerous important
factors, risks, and uncertainties that may cause actual events or
results to differ materially from our current expectations. These
and other risks and uncertainties are more fully described in our
periodic filings with the Securities and Exchange Commission (SEC),
including the risk factors described in the section entitled “Risk
Factors” in the quarterly and annual reports that we file with the
SEC. Any forward-looking statements that we make in this
presentation speak only as of the date of this presentation. Except
as required by law, we assume no obligation to update
forward-looking statements contained in this presentation whether
as a result of new information, future events, or otherwise, after
the date of this presentation.
Contact:Tiffany HamiltonHead of
CommunicationsIR@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2024 to May 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2023 to May 2024